A phase 1 dose-escalating study of pegylated recombinant human arginase 1 (Peg-rhArg1) in patients with advanced hepatocellular carcinoma

Yau, Thomas; N. Cheng, Paul; Chan, Pierre; Chan, William; Chen, Li; Yuen, Jimmy; Pang, Roberta; Tat Fan, Sheung; T.P. Poon, Ronnie

doi:10.1007/s10637-012-9807-9

Public

A phase 1 dose-escalating study of pegylated recombinant human arginase 1 (Peg-rhArg1) in patients with advanced hepatocellular carcinoma

Published in Investigational New Drugs • Mar 16, 2012

Authors:

Thomas Yau

Paul N. Cheng

Pierre Chan

Abstract

BACKGROUND: Hepatocellular carcinoma (HCC) cells are auxotrophic for arginine, depletion of which leads to tumour regression. The current study evaluated safety, pharmacokinetics (PK)/ pharmacodynamics (PD) parameters, and potential anti-tumor activity of pegylated recombinant human arginase 1 (peg-...

Subject

Hepatocellular carcinoma

Arginase

PEG ratio

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!